CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 77 enrolled
Drug / intervention
Dapsone Formulation A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01773122
NCT01773122Phase 1Completed
CompareCT.gov

Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

Allergan·interventional·Posted Jan 23, 2013·Updated Apr 24, 2019

In Brief

A Phase 1 clinical trial evaluating Dapsone Formulation A, Dapsone Formulation B, and 2 other interventions for Acne Vulgaris. Completed, enrolled 77 participants across 1 site.

Detailed Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 23, 2013
Enrollment StartJan 21, 2013
Primary CompletionMay 5, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.4 years ago

Interventions

Dapsone Formulation Adrug

Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.

Dapsone Formulation Bdrug

Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.

Dapsone Formulation Cdrug

Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.

Dapsone 5% Geldrug

Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.